（Securities Code 7702）

Financial Statements
for the 1st Quarter of Fiscal Year Ending March 31, 2025
(From Apr. 1, 2024 to Jun. 30, 2024)

Summary of consolidated results
August 9, 2024

©️ JMS CO.,LTD. All Rights Reserved.

Summary of Financial Results
Consolidated
Increase in sales
Increase in profit

Net sales
16,177 million yen (+1,576 million yen)
Operating profit
42 million yen ( +154 million yen)

Sales :

Domestic sales increased due to growth in Oncology Therapy and Enteral Nutrition as well as
the effect of price pass-on. Overseas sales increased due to growth in Blood Management & Cell
Therapy and Dialysis, as well as an increase in yen-denominated sales resulting from thedepreciation of the yen.

Profit :Increase due to growth of mainstay products in Japan and overseas, and increase in revenue
from price pass-on that proceeded from the previous fiscal year, despite the impact of cost
increases in raw materials and labor costs, etc.

Sales by Business Segment
Prefilled Syringes grew with the drug price revision, while Hemodialysis Machines anddialysis related equipment increased in China.

Dialysis :BloodApheresis Kits and Blood Bags continued to grow, and the addition of Leukocyte
Management and Reduction Filters business acquired in the previous fiscal year contributed to theCell Therapy：
increase in sales.

Sales by Region
Asia :In addition to Blood Bags, Hemodialysis Machines, and dialysis related equipment, andLeukocyte Reduction Filters Increase in China

Japan :

Closed Drug Mixing/Infusion Systems remained strong, while Prefilled Syringes and Dysphagiarelated products increased due to the drug price and the revision of medical service fees.
2©️ JMS CO.,LTD. All Rights Reserved.

Highlights in Business Results(unit: JPY million)

Year– over – Year

Apr. - Jun. 2023
Results

Apr. - Jun. 2024
Results

Net sales

14,60016,177

1,576

10.8%

Operating profit

(111)

42154

―

Ordinary profit

(73)

194

267

―

Profit attributable toowners of parent

(260)

(92)

168

―

Net sales

Operating profit

Diff.

Profit attributable toowners of parent

Ordinary profit

16,177
13,57913,797

14,281%

14,600

659

685
630

365

478

436

194

42(104)
Apr. - Jun. Apr. - Jun. Apr. - Jun. Apr. - Jun. Apr. - Jun.
2020
2021
2022
20232024

(36)

(78)

(111)

Apr. - Jun. Apr. - Jun. Apr. - Jun. Apr. - Jun. Apr. - Jun.
2020
2021
2022
2023
2024

(73)

Apr. - Jun. Apr. - Jun. Apr. - Jun. Apr. - Jun. Apr. - Jun.
2020
2021
2022
2023
2024

©️ JMS CO.,LTD. All Rights Reserved.

(92)
(260)

Apr. - Jun. Apr. - Jun. Apr. - Jun. Apr. - Jun. Apr. - Jun.
2020
2021
2022
2023
2024

3

Summary by segment (geographical area)[Japan]Increase in Closed Drug Mixing/Infusion Systems and Hemodialysis Machines for China, as well as increase in Prefilled Syringes due
to drug price revision, and price pass-on from the previous fiscal year, resulted in increase in sales and profit.

[Singapore] Increase due to higher revenue and foreign exchange gains, despite continued growth Apheresis Kits and Blood Bags, higher
raw material and electricity costs, and higher labor costs in preparation for increased demand.

(unit: JPY million)

Apr. - Jun.
2023
Japan
Singapore※
China
Philippines
Germany

Others※Year-over-Year

Apr. - Jun.
2024

Diff.

%

Sales

9,887

10,705817

8.3%

Ordinary profit(64)252316―

Sales

5,030

5,738

708

14.1%

Ordinary profit(59)40100―

Sales

969

1,010

404.2%

Ordinary profit

(4)

(36)

(31)

―

Sales

899

911

111.3%

Ordinary profit

14(149)

(164)

―

Sales

1,058

938(120)(11.4)%

Ordinary profit

13274(58)(43.9)%

Sales

1,016

1,152

135

13.3%

Ordinary profit

10(12)(22)―※Singapore : This segment includes Indonesian subsidiary.
※Others : This segment includes business activity of subsidiaries in Japan, United States, South Korea , Thailand and Part of China.

©️ JMS CO.,LTD. All Rights Reserved.

4

Sales by Business Segment(unit: JPY million)

Infusion & Nutrition
5,738

5,839

Apr. - Jun. 2023

Dialysis

Sales of Closed Drug Mixing/Infusion Systems
remained steady, while sales of Dysphagia-related
products increased due to the revision of medical
service fees, but sales of Medical Gloves
decreased, resulting in a slight increase.

Net sales

1,298

Apr. - Jun. 2023

Apr. - Jun. 2024

Prefilled Syringes grew with drug price revision,
Hemodialysis Machines and dialysis related
equipment for China increased.

Blood Management& Cell Therapy
Apr. - Jun. 2023

Apr. - Jun. 2024

Sales of Acute Blood Purification remained
steady, but a decrease in sales ofCardiopulmonary Blood Tubing Sets andHemoconcentrators resulted in a slight decrease.

Net sales

4,015

Net sales

Cardiovascular
1,334

4,810

Apr. - Jun. 2024

3,920
3,172

Net sales©️ JMS CO.,LTD. All Rights Reserved.

Apr. - Jun. 2023

Apr. - Jun. 2024

Apheresis Kits and Blood Bags continued to grow,and Leukocyte Reduction Filter, business acquiredin the previous fiscal year, contributed to increasein sales.

5Sales by Region (Customer's Location)
In Japan, Closed Drug Mixing/Infusion Systems remained strong, and sales increased due to an increase in Prefilled Syringes and Dysphagia-related
products as a result of the drug price revision and the revision of medical service fees. Overseas, Apheresis Kits and Blood Bags continued to grow,
Hemodialysis Machines for China also increased, and sales increased in all regions except Europe, where AV Fistula Needles decreased.

(unit: JPY million)

Apr. - Jun.
2023

Apr. - Jun.
2024

Year-over-YearDiff.

Sales
composition%

Japan

8,848

9,248

400

4.5%

57.2%

Asia

2,296

3,200904

39.4%

19.8%

North America

1,716

1,923

207

12.1%

11.9%

Europe1,474

1,408(65)(4.5)%

8.7%

Others264395

130

49.4%

2.4%

6©️ JMS CO.,LTD. All Rights Reserved.

Ordinary profit : Compared with the previous year
Despite the impact of increased costs in raw materials and labor, profit increased due to the growth of mainstay products in Japan andoverseas, revenue gains from price shift initiated in the previous fiscal year, non-operating income from equity in earnings of affiliates, andthe favorable impact of foreign exchange rate fluctuations.

(unit: JPY million)*The underlined figures exclude impact of exchange rate.

Exchange Rate (average during period)
US Dollar(unit: JPY)EuroSingapore
DollarApr. - Jun. 2023

137.37142.10102.54

Apr. - Jun. 2024

155.88161.31115.21©️ JMS CO.,LTD. All Rights Reserved.

7

Forecast for FYE Mar. 2025
Consolidated business forecast for the fiscal year ending March 31, 2025 released on May 14, 2024 has not been revised.

(unit: JPY million)FYE Mar. 2024
ResultFYE Mar. 2025
Forecast

Net sales

65,29270,000

7.2％

Operating profit

(268)

800

―

Ordinary profit

145

800

448.0%

Profit attributable toowners of parent

(36)

400

―

Year-over-Year＊Exchange rate for the forecast: 1USD=145yen, 1EUR=156yen, 1SGD=106yen.

Sales：

Continued revenue growth is expected due to steady demand in Japan and overseas.

Profit：Although the company continues to be affected by rising costs, such as raw material and labor costs, it expects toachieve a profit recovery through further cost reductions, in addition to the effect of increased sales, such as
growth in mainstay products and price pass-on.

8©️ JMS CO.,LTD. All Rights Reserved.

TOPICSMay 2024
Signed an agreement with Teijin Pharma Limited to establish a joint venturecompany focusing on peritoneal dialysis
The joint venture aims to expand the home peritoneal dialysis market by leveraging Teijin Pharma's homehealthcare know-how and community comprehensive care business with JMS's peritoneal dialysis business.

Peritoneal dialysis solutions "Perisate"

June 2024

Automatic Peritoneal Dialysis Machines"Automatic Peritoneal Dialysis Machines PD-Relaxa"

JMS Dalian Signs Exclusive Sales Cooperation Agreement with Terumo Medical(Shanghai) Co., Ltd.
JMS Dalian Medical Supply Co., Ltd. a JMS group company, has signed an exclusive sales cooperation agreementwith Terumo Medical (Shanghai) Co., Ltd. for heat exchangers for artificial heart lungs in China. We will
cooperate with Terumo Medical (Shanghai) Co., Ltd. to ensure medical safety and expand our market share in
the Chinese market.

Heat exchanger for artificial heart-lung"JMS Heat Exchanger"©️ JMS CO.,LTD. All Rights Reserved.

Myocardial protection circuit incorporating"JMS heat exchanger"

9The assessment figures described on this report are based on available information
at this moment, including uncertain data. Actual results may be different from the figures.